Latest & greatest articles for thyroid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on thyroid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on thyroid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for thyroid

141. Thyroid cancer

Thyroid cancer Thyroid cancer - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Thyroid cancer Last reviewed: February 2019 Last updated: November 2017 Summary Most commonly presents as an asymptomatic thyroid nodule detected by palpation or ultrasound in a woman in her 30s or 40s. The most important diagnostic test is fine-needle aspiration. Treatment is usually total thyroidectomy followed by radioactive iodine (...) ablation and TSH suppression (papillary or follicular). Treatment differs and must be tailored for uncommon types of thyroid cancer such as medullary, lymphoma, or anaplastic. Prognosis depends on risk-group stratification. Definition Four types account for more than 98% of thyroid malignancies: papillary, follicular, anaplastic, and medullary. Gimm O. Thyroid cancer. Cancer Lett. 2001 Feb 26;163(2):143-56. http://www.ncbi.nlm.nih.gov/pubmed/11165748?tool=bestpractice.com History and exam presence

2017 BMJ Best Practice

142. Toxic thyroid adenoma

Toxic thyroid adenoma Toxic thyroid adenoma - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Toxic thyroid adenoma Last reviewed: February 2019 Last updated: February 2019 Summary Typically a single large thyroid nodule accompanied by clinical and biochemical hyperthyroidism. Diagnosis confirmed by thyroid scan demonstrating a hot area and suppression of extranodular thyroid tissue. Hyperthyroidism caused by toxic (...) adenomas generally does not remit. Definitive treatment, such as radioactive iodine therapy, is usually required. Complications of untreated toxic adenomas may include sequelae of hyperthyroidism such as cardiac dysfunction or bone loss, or tracheal compression by large nodules. Definition A toxic adenoma is an autonomously functioning thyroid nodule that causes hyperthyroidism. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management

2017 BMJ Best Practice

143. Thyroid Cancer: Screening

Thyroid Cancer: Screening Final Recommendation Statement: Thyroid Cancer: Screening - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 11/16/2018 6:27:19 PM You are here: Final Recommendation Statement : Final Recommendation Statement Final Recommendation Statement Thyroid Cancer: Screening Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency (...) for Healthcare Research and Quality or the U.S. Department of Health and Human Services. Recommendation Summary Population Recommendation Grade Adults The USPSTF recommends against screening for thyroid cancer in asymptomatic adults. To read the recommendation statement in JAMA , select . To read the evidence summary in JAMA , select . Table of Contents Preface The US Preventive Services Task Force (USPSTF) makes recommendations about the effectiveness of specific preventive care services for patients

2017 U.S. Preventive Services Task Force

144. BRAF(V600E) mutation as a predictor of thyroid malignancy in indeterminate nodules: A systematic review and meta-analysis. (PubMed)

BRAF(V600E) mutation as a predictor of thyroid malignancy in indeterminate nodules: A systematic review and meta-analysis. Thyroid nodules are usually diagnosed using fine-needle aspiration (FNA). The sensitivity limitations of FNA result in 10-30% of nodules being classified as "indeterminate". The BRAFV600E mutation is associated with papillary thyroid carcinoma (PTC). We conducted a systemic review and meta-analysis to evaluate the diagnostic utility of the BRAFV600E mutation (...) in indeterminate nodules.PUBMED and EMBASE were searched for studies testing for the BRAFV600E involving indeterminate nodules (Thy3a, Thy3f, Thy4) and containing information on final surgical histopathology. Thirty two studies involving 3150 indeterminate nodules were included in the analysis.The overall sensitivity and specificity for BRAFV600E for the diagnosis of thyroid malignancy was 0.40 (95% CI: 0.32-0.48) and 1.00 (95% CI: 0.98-1.00) respectively. The diagnostic odds ratio (DOR) was 205.4 (95% CI

Full Text available with Trip Pro

2016 European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

145. Activated charcoal for preoperative localization of thyroid cancer recurrence

Activated charcoal for preoperative localization of thyroid cancer recurrence Activated charcoal for preoperative localization of thyroid cancer recurrence Activated charcoal for preoperative localization of thyroid cancer recurrence Klappenbach R, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A, López A, Rey-Ares L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Klappenbach R, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A, López A, Rey-Ares L. Activated charcoal for preoperative localization of thyroid cancer recurrence. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No. 501. 2016 Authors' conclusions Very low-quality evidence does not allow drawing conclusions on activated charcoal for preoperative localization

2016 Health Technology Assessment (HTA) Database.

146. Association between screening and the thyroid cancer "epidemic" in South Korea: evidence from a nationwide study. (PubMed)

Association between screening and the thyroid cancer "epidemic" in South Korea: evidence from a nationwide study.  To investigate whether screening for thyroid cancer led to the current "epidemic" in South Korea. Review of the medical records of nationally representative samples of patients with a diagnosis of thyroid cancer in 1999, 2005, and 2008. Sample cases were randomly selected from South Korea's nationwide cancer registry, using a systematic sampling method after stratification (...) by region. 5796 patients with thyroid cancer were included (891 in 1999, 2355 in 2005, and 2550 in 2008). The primary outcome was age standardised incidence of thyroid cancer and the changes in incidence between 1999 and 2008 according to the methods used to detect tumours (screen detection versus clinical detection versus unspecified). Between 1999 and 2008, the incidence of thyroid cancer increased 6.4-fold (95% confidence interval 4.9-fold to 8.4-fold), from 6.4 (95% confidence interval 6.2 to 6.6

Full Text available with Trip Pro

2016 BMJ

147. Routine Prenatal Thyroid-Stimulating Hormone Testing: Evidence-Based Guidelines

Routine Prenatal Thyroid-Stimulating Hormone Testing: Evidence-Based Guidelines Routine Prenatal Thyroid-Stimulating Hormone Testing: Evidence-Based Guidelines | CADTH.ca Find the information you need Routine Prenatal Thyroid-Stimulating Hormone Testing: Evidence-Based Guidelines Routine Prenatal Thyroid-Stimulating Hormone Testing: Evidence-Based Guidelines Published on: November 14, 2016 Project Number: RB1038-000 Product Line: Research Type: Other Diagnostics Report Type: Summary (...) of Abstracts Result type: Report Question What are the evidence-based guidelines for routine screening of thyroid-stimulating hormone in prenatal women? Key Message Four evidence-based guidelines were identified regarding routine screening of thyroid-stimulating hormone in prenatal women. Tags fear, fetus, pregnancy, pregnancy trimesters, pregnant women, thyroid diseases, thyroid function tests, thyrotropin, laboratory tests, Prenatal, foetus, iodine test, thyrotrophin, pregnant women, thyroid stimulating

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

148. Minimally invasive and remote‐access thyroid surgery in the era of the 2015 American Thyroid Association guidelines (PubMed)

Minimally invasive and remote‐access thyroid surgery in the era of the 2015 American Thyroid Association guidelines Thyroid surgery has evolved throughout the years from being one of the most dangerous surgeries to becoming one of the safest surgical procedures performed today. Recent technologic innovations have allowed surgeons to remove the thyroid gland from a remote site while avoiding visible neck scars. There are many endoscopic approaches for thyroidectomy. The most common cervical (...) the surgeons in accomplishing remote-access thyroid surgery under the scope of the 2015 American Thyroid Association Guidelines.

Full Text available with Trip Pro

2016 Laryngoscope investigative otolaryngology

149. Newborn Screening for Thyroid-stimulating Hormone as an Indicator for Assessment of Iodine Status in the Republic of Macedonia (PubMed)

Newborn Screening for Thyroid-stimulating Hormone as an Indicator for Assessment of Iodine Status in the Republic of Macedonia Iodine deficiency is associated with goiter and impaired brain function leading to cretinism. An increased frequency of thyroid-stimulating hormone (TSH) measurements above 5 mlU/L on newborn screening points toward an impaired iodine status of the population.A 13-year retrospective analysis was performed in 228,266 newborns participating in the national thyroid newborn

Full Text available with Trip Pro

2016 Journal of medical biochemistry

150. Thyroid Stimulating Hormone (TSH) in the Evaluation of Subclinical Hypothyroidism (PubMed)

Thyroid Stimulating Hormone (TSH) in the Evaluation of Subclinical Hypothyroidism 27755618 2016 11 07 2018 11 13 1538-3598 316 15 2016 Oct 18 JAMA JAMA Thyroid-Stimulating Hormone in the Evaluation of Subclinical Hypothyroidism. 1592-1593 10.1001/jama.2016.9534 Papaleontiou Maria M Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor. Cappola Anne R AR Division of Endocrinology, Diabetes, and Metabolism, Perelman School of Medicine at the University

Full Text available with Trip Pro

2016 JAMA

151. Lacrimal gland enlargement as an early clinical or radiological sign in thyroid orbitopathy (PubMed)

Lacrimal gland enlargement as an early clinical or radiological sign in thyroid orbitopathy Characteristic ophthalmic signs of Thyroid Orbitopathy (TO) include exophthalmos, eyelid retraction, eyelid edema, restrictive extraocular myopathy, and optic neuropathy. In addition lacrimal gland (LG) enlargement can be observed in these patients. However TO has not usually been considered in the differential diagnosis of cases of isolated LG enlargement.A female patient at our institution (Texas Tech (...) to better understand the timing of LG involvement. In patients presenting with lacrimal gland enlargement, thyroid orbitopathy should be strongly considered in the differential diagnosis together with other causes of dacryoadenitis and LG tumors. This may save unnecessary and extensive diagnostic testing or even LG biopsies.

Full Text available with Trip Pro

2016 American journal of ophthalmology case reports

152. Lenvima for Differentiated Thyroid Cancer – Details

Lenvima for Differentiated Thyroid Cancer – Details Lenvima for Differentiated Thyroid Cancer – Details | CADTH.ca Find the information you need Lenvima for Differentiated Thyroid Cancer – Details Lenvima for Differentiated Thyroid Cancer – Details Project Number pCODR 10080 Brand Name Lenvima Generic Name Lenvatinib Strength 4mg and 10mg Capsules Tumour Type Endocrine Indication Differentiated Thyroid Cancer Funding Request For the treatment of patients with locally recurrent or metastatic

2016 CADTH - Pan Canadian Oncology Drug Review

153. Intraoperative Neuromonitoring in Thyroid Surgery: A Systematic Review (PubMed)

Intraoperative Neuromonitoring in Thyroid Surgery: A Systematic Review This study aimed to assess the efficacy of intraoperative neurophysiologic monitoring (IONM) in preventing recurrent laryngeal nerve palsy (RLNP) during thyroid surgery. When IONM results in false positives, it seeks to evaluate contributing factors. A systematic review was conducted gauging the predictive power of neuromonitoring in determining RLN function intraoperatively, its reductions of temporary and permanent RLNP (...) rates, and surgeons' response to the technology. MEDLINE, EMBASE, and PubMed were searched for RLN monitoring in thyroid surgery following a set of inclusion/exclusion criteria. Seventeen studies comparing thyroid surgery with and without IONM were reviewed, including 30,926 patients. Selected studies were pooled to gage the predictive power. Mean specificity of IONM in identifying functional nerves was 90.24 % among 7366 nerves at risk (NAR). However, mean positive predictive power (PPP) was low

2016 EvidenceUpdates

154. Worldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis. (PubMed)

Worldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis. 27532827 2016 08 23 2016 08 18 1533-4406 375 7 2016 Aug 18 The New England journal of medicine N. Engl. J. Med. Worldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis. 614-7 10.1056/NEJMp1604412 Vaccarella Salvatore S From the International Agency for Research on Cancer, Lyon, France (S.V., S.F., F.B., C.P.W., M.P.); and the Cancer Epidemiology Unit, CRO (Centro di Riferimento Oncologico) Aviano (...) Male Medical Overuse trends Middle Aged Thyroid Neoplasms diagnosis epidemiology Young Adult 2016 8 18 6 0 2016 8 18 6 0 2016 8 24 6 0 ppublish 27532827 10.1056/NEJMp1604412

2016 NEJM

155. Thyroid Ophthalmopathy, Dermopathy, and Acropachy. (PubMed)

Thyroid Ophthalmopathy, Dermopathy, and Acropachy. 27468062 2016 08 09 2016 07 29 1533-4406 375 3 2016 Jul 21 The New England journal of medicine N. Engl. J. Med. IMAGES IN CLINICAL MEDICINE. Thyroid Ophthalmopathy, Dermopathy, and Acropachy. 261 10.1056/NEJMicm1506674 Guerrero Carlo C Maricopa Medical Center, Phoenix, AZ carlo_guerrero@dmgaz.org. Pittelkow Mark R MR Mayo Clinic, Scottsdale, AZ. eng Case Reports Journal Article United States N Engl J Med 0255562 0028-4793 AIM IM Fingers

Full Text available with Trip Pro

2016 NEJM

156. Use of imaging tests after primary treatment of thyroid cancer in the United States: population based retrospective cohort study evaluating death and recurrence. (PubMed)

Use of imaging tests after primary treatment of thyroid cancer in the United States: population based retrospective cohort study evaluating death and recurrence.  To determine whether the use of imaging tests after primary treatment of differentiated thyroid cancer is associated with more treatment for recurrence and fewer deaths from the disease. Population based retrospective cohort study. Surveillance Epidemiology and End Results-Medicare database in the United States. 28 220 patients (...) diagnosed with differentiated thyroid cancer between 1998 and 2011. The study cohort was followed up to 2013, with a median follow-up of 69 months. Treatment for recurrence of differentiated thyroid cancer (additional neck surgery, additional radioactive iodine treatment, or radiotherapy), and deaths due to differentiated thyroid cancer. We conducted propensity score analyses to assess the relation between imaging (neck ultrasound, radioiodine scanning, or positron emission tomography (PET) scanning

Full Text available with Trip Pro

2016 BMJ

157. LENVIMA (lenvatinib), protein kinase inhibitor - thyroid carcinoma

LENVIMA (lenvatinib), protein kinase inhibitor - thyroid carcinoma LENVIMA SUMMARY CT14510

2016 Haute Autorite de sante

158. Ultrasound-guided percutaneous radiofrequency ablation for benign thyroid nodules

Ultrasound-guided percutaneous radiofrequency ablation for benign thyroid nodules Ultr Ultrasound-guided percutaneous r asound-guided percutaneous radiofrequency adiofrequency ablation for benign th ablation for benign thyroid nodules yroid nodules Interventional procedures guidance Published: 22 June 2016 nice.org.uk/guidance/ipg562 Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When (...) and efficacy of ultrasound-guided percutaneous radiofrequency ablation for benign thyroid nodules is adequate to support the use of this procedure provided that standard arrangements are in place for clinical governance, consent and audit. © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 1 of 82 2 Indications and current treatments Indications and current treatments 2.1 Thyroid nodules may be cystic, colloid, hyperplastic

2016 National Institute for Health and Clinical Excellence - Interventional Procedures

159. [Dose-Response Dependences for Frequency of RET/PTC Gene Rearrangements in Papillary Thyroid Carcinoma after Irradiation. Simple Pooling Analysis of Molecular Epidemiological Data]. (PubMed)

[Dose-Response Dependences for Frequency of RET/PTC Gene Rearrangements in Papillary Thyroid Carcinoma after Irradiation. Simple Pooling Analysis of Molecular Epidemiological Data]. On the basis of all possible publications on the theme included in the previously formed base of sources on molecular epidemiology of RET/PTC rearrangements in thyroid papillary carcinoma a pooled analysis ("simple pooling data") on determination of the dose-effect dependences for RET/PTC frequency in radiogenic (...) carcinomas of various irradiated groups was performed. (They are groups subjected to radiotherapeutic exposure, residents near the Chernobyl nuclear power plant (CNPP) and victims of nuclear bombing). The tendency to Pearson linear correlation (r = 0.746; p = 0.148) between the frequency of RET/PTC and the estimated dose on thyroid in the regions affected by the CNPP accident was revealed. But this tendency was recognized to be random owing to abnormally low values of the indicator for the most

2016 Radiatsionnaia biologiia, radioecologiia / Rossiĭskaia akademiia nauk

160. Thyroid cancer. (PubMed)

Thyroid cancer. Thyroid cancer is the fifth most common cancer in women in the USA, and an estimated over 62 000 new cases occurred in men and women in 2015. The incidence continues to rise worldwide. Differentiated thyroid cancer is the most frequent subtype of thyroid cancer and in most patients the standard treatment (surgery followed by either radioactive iodine or observation) is effective. Patients with other, more rare subtypes of thyroid cancer-medullary and anaplastic-are ideally (...) treated by physicians with experience managing these malignancies. Targeted treatments that are approved for differentiated and medullary thyroid cancers have prolonged progression-free survival, but these drugs are not curative and therefore are reserved for patients with progressive or symptomatic disease.Copyright © 2016 Elsevier Ltd. All rights reserved.

2016 Lancet